carnitine has been researched along with Diabetic Cardiomyopathies in 4 studies
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Whether differences in circulating long chain acylcarnitines (LCAC) are seen in heart failure (HF) patients with and without diabetes mellitus (DM), and whether these biomarkers report on exercise capacity and clinical outcomes, remains unknown." | 8.02 | Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. ( Bain, J; Felker, GM; Giamberardino, SN; Ilkayeva, O; Kraus, WE; McGarrah, RW; Newgard, CB; O'Connor, CM; Regan, JA; Shah, SH; Truby, LK, 2021) |
| "Whether differences in circulating long chain acylcarnitines (LCAC) are seen in heart failure (HF) patients with and without diabetes mellitus (DM), and whether these biomarkers report on exercise capacity and clinical outcomes, remains unknown." | 4.02 | Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. ( Bain, J; Felker, GM; Giamberardino, SN; Ilkayeva, O; Kraus, WE; McGarrah, RW; Newgard, CB; O'Connor, CM; Regan, JA; Shah, SH; Truby, LK, 2021) |
| "L-carnitine treatment enhanced microvascular perfusion, reinforced endothelial barrier function, repressed the endothelial inflammatory response, and maintained the microvascular structure in db/db mice." | 1.91 | L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways. ( Chen, A; Chen, J; Chen, Y; Chen, Z; Ge, J; Li, C; Li, Q; Li, S; Li, Y; Liu, M; Lu, D; Qian, J; Shen, L; Xia, Y; Xu, F; Yan, X; Yin, M; Zhou, Y, 2023) |
| "Acylcarnitine is an intermediate product of fatty acid oxidation." | 1.62 | Medium & long-chain acylcarnitine's relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study. ( An, ZN; Ge, MH; Jiang, DW; Liu, C; Shen, XL; Wei, DZ; Xing, XJ; Zheng, DM, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, DM | 1 |
| An, ZN | 1 |
| Ge, MH | 1 |
| Wei, DZ | 1 |
| Jiang, DW | 1 |
| Xing, XJ | 1 |
| Shen, XL | 1 |
| Liu, C | 1 |
| Li, S | 1 |
| Liu, M | 1 |
| Chen, J | 1 |
| Chen, Y | 1 |
| Yin, M | 1 |
| Zhou, Y | 1 |
| Li, Q | 1 |
| Xu, F | 1 |
| Li, Y | 1 |
| Yan, X | 1 |
| Xia, Y | 1 |
| Chen, A | 1 |
| Lu, D | 1 |
| Li, C | 1 |
| Shen, L | 1 |
| Chen, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Truby, LK | 1 |
| Regan, JA | 1 |
| Giamberardino, SN | 1 |
| Ilkayeva, O | 1 |
| Bain, J | 1 |
| Newgard, CB | 1 |
| O'Connor, CM | 1 |
| Felker, GM | 1 |
| Kraus, WE | 1 |
| McGarrah, RW | 1 |
| Shah, SH | 1 |
| Ruiz, M | 1 |
| Coderre, L | 1 |
| Lachance, D | 1 |
| Houde, V | 1 |
| Martel, C | 1 |
| Thompson Legault, J | 1 |
| Gillis, MA | 1 |
| Bouchard, B | 1 |
| Daneault, C | 1 |
| Carpentier, AC | 1 |
| Gaestel, M | 1 |
| Allen, BG | 1 |
| Des Rosiers, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)[NCT00047437] | Phase 3 | 2,331 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for carnitine and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Medium & long-chain acylcarnitine's relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study.
Topics: Adult; Aminoimidazole Carboxamide; Animals; Biomarkers; Carnitine; Cell Line; Diabetes Mellitus, Typ | 2021 |
L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways.
Topics: Animals; Carnitine; Diabetes Mellitus; Diabetic Cardiomyopathies; Endothelial Cells; Male; Mice; Mit | 2023 |
Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy.
Topics: Aged; Biomarkers; Carnitine; Clinical Trials as Topic; Diabetic Cardiomyopathies; Exercise Tolerance | 2021 |
MK2 Deletion in Mice Prevents Diabetes-Induced Perturbations in Lipid Metabolism and Cardiac Dysfunction.
Topics: Animals; Carnitine; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fatty Acids, Noneste | 2016 |